Division of Rheumatology and Clinical Immunology, University of Pittsburgh, BST S723, 3500 Terrace Street, Pittsburgh, PA 15261, USA.
Harvard Medical School, Boston, MA, USA; Clinical Epidemiology Program, Mongan Institute, Massachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA 02114, USA; Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Rheum Dis Clin North Am. 2023 Aug;49(3):695-711. doi: 10.1016/j.rdc.2023.03.007. Epub 2023 Mar 14.
The coronavirus disease 2019 (COVID-19) pandemic has led to the emergence of multiple challenges in the care of patients with systemic rheumatic diseases. Patients with vasculitis represent a group of particular concern due to existing risk factors which include a higher burden of comorbidities and specific immunosuppressive therapies used for treatment. Vaccination and the use of other risk mitigation strategies are crucial for the care of these patients. This review provides an overview of existing evidence to contribute to the understanding and specific requirements of the treatment and management of patients with vasculitis during the time of COVID-19.
2019 年冠状病毒病（COVID-19）大流行给系统性风湿病患者的护理带来了诸多挑战。血管炎患者是一个特别令人关注的群体，因为他们存在多种现有风险因素，包括更高的合并症负担和用于治疗的特定免疫抑制疗法。疫苗接种和使用其他风险缓解策略对这些患者的护理至关重要。本综述提供了现有证据的概述，有助于理解和确定 COVID-19 期间血管炎患者的治疗和管理的具体要求。
